Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olmesartan Medoxomil in Established Atherosclerosis (AIMS)
NCT00382213Phase 3Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Jun 2000
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in atherosclerosis comparing Olmesartan medoxomil with Placebo (2 arms). Primary endpoint: Composite of ten circulating surrogate markers of atherosclerosis for vascular inflammation at 1 year. Started Jun 2000; status: completed.
02
Drugs
olmesartan
03
Conditions
atherosclerosis
Beyond the preview
Go deeper on NCT00382213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00382213.